Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT00478218Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Objective Response Rate up to 5 years. Started Jul 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00478218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478218.